Valerio Therapeutics Announces Development Collaboration with Abivax and Provides Pipeline Update
Valerio and Abivax enter into a binding term-sheet for an exclusive global research and development collaboration
Under the terms of the agreement Valerio will receive an upfront payment up to approximately €2.4 million and would be eligible to receive development and commercial milestone payments, as well as royalties on net sales and sublicensing revenues, subject to execution of the definitive agreement
Further, Valerio provides pipeline update highlighting three proprietary precision RNA therapeutics programs, including lead candidates VTX-001 and VTX-002 in immunity and inflammation
Company targets nomination of up to two development candidates within 12–18 months and advancement of at least one program into first-in-human studies within 18–24 months
